News
NICE recommends Lynparza for maintenance treatment of relapsed, platinum-sensitive high grade epithelial ovarian, fallopian tube or peritoneal cancer if they have a BRCA1 or BRCA2 mutation (BRCAm).- AstraZeneca + Merck Inc.
AstraZeneca and MSD have announced that NICE has expanded its recommendation for Lynparza (olaparib) tablets for women with relapsed, BRCA-mutated, advanced ovarian cancer. Olaparib is now recommended by the National Institute for Health and Care Excellence (NICE) for maintenance treatment of relapsed, platinum-sensitive high grade epithelial ovarian, fallopian tube or peritoneal cancer in adults whose disease has responded to platinum-based chemotherapy if they have a BRCA1 or BRCA2 mutation (BRCAm).
Lynpraza will be made available to patients within NHS England and Wales via routine commissioning if they have had three or more courses of platinum-based chemotherapy; and to patients within NHS England via the Cancer Drugs Fund (CDF) if they have had two courses of platinum-based chemotherapy.
Condition: Ovarian Cancer
Type: drug